Peer-reviewed veterinary case report
P16 protein levels studied in bone cancer of large breed dogs
By Murphy, B G et al.·Published in BMC veterinary research·2017·Department Pathology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of P16 expression in canine appendicular osteosarcoma.
- Species:
- dog
Plain-English summary
A large breed dog diagnosed with osteosarcoma (a type of bone cancer) often faces a tough battle, as most dogs with this condition have hidden lung tumors at the time of diagnosis. Even with surgery and chemotherapy, many dogs live less than a year after being diagnosed. Researchers looked at a specific protein called P16 in the tumor tissue to see if it could help predict which dogs might respond better to treatment. While they found a trend suggesting that dogs without P16 might have a shorter time without disease, more research is needed to confirm these findings.
People also search for: dog osteosarcoma treatment · large breed dog bone cancer · P16 expression in dog tumors
Abstract
BACKGROUND: Osteosarcoma (OSA) is a common malignant bone tumor of large breed dogs that occurs at predictable anatomic sites. At the time of initial diagnosis, most affected dogs have occult pulmonary metastases. Even with aggressive surgical treatment combined with chemotherapy, the majority of dogs diagnosed with OSA live less than 1 year from the time of diagnosis. The ability to identify canine OSA cases most responsive to treatment is needed. In humans, OSA is also an aggressive tumor that is histologically and molecularly similar to canine OSA. The expression of the tumor suppressor gene product P16 by human OSA tissue has been linked to a favorable response to chemotherapy. RESULTS: We identified an antibody that binds canine P16 and developed a canine OSA tissue microarray in order to test the hypothesis that P16 expression by canine OSA tissue is predictive of clinical outcome following amputation and chemotherapy. Although statistical significance was not reached, a trend was identified between the lack of canine OSA P16 expression and a shorter disease free interval. CONCLUSIONS: The identification of a molecular marker for canine OSA is an important goal and the results reported here justify a larger study.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28633676/